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INTRODUCTION 
Hemophilia patients usually have a lower incidence 
of coronary artery disease (CAD).1 However, as their 
life expectancy increases so does the incidence of CAD. 
Anti-platelet drugs, diagnostic coronary catheterization, 
angioplasty and coronary artery bypass surgery (CABG) 
have rarely been used in this population.2 
CASE DESCRIPTION
In this case-report, we describe the case of a 37-year-old 
man with severe type B hemophilia, HIV (on antiretroviral 
treatment) and activity-limiting angina unresponsive to 
clinical treatment. Myocardial cintilography detected 
ventricular dysfunction with lateral and inferior ischemia. 
Coronarography was performed with specific hematological 
support. The patient received enough factor IX to reach 
100% plasma concentration (6,500 IU), followed by 3,500 
IU the next day. Severe coronary obstructions were observed 
during coronarography (Figure 1). 
The patient then underwent an off-pump CABG with an 
appropriate factor IX infusion (6,500 IU pre-surgery, 2,000 
IU post-surgery with continuous infusion in order to keep 
the plasma concentration at 40% for the first 2 days, 30% 
for the third through sixth days, and 20% for the seventh 
through twelfth days). Two grafts were performed (left 
internal thoracic artery to anterior descending artery and 
saphenous graft to circumflex artery), and no adverse cardiac 
or hematological events occurred. After surgery, the patient 
was not treated with anti-platelet drugs.
Six months after CABG, activity-limiting angina, 
ischemia and ventricular dysfunction persisted. An 
angiotomography showed obstruction of the saphenous 
vein graft. We performed an angioplasty of the circumflex 
coronary artery with a bare metal stent and used factor 
IX during the procedure, as described for the previous 
coronarography. The patient was treated with heparin, 
clopidogrel and acetyl salicylic acid (ASA). Clopidogrel 
Figure 1 - A. Circumflex coronary artery with 95% obstruction. B. Anterior 
descending coronary artery with 70% obstruction. C. Right coronary artery 
with a 100% distal occlusion823
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was administered for 30 days, and ASA was prescribed 
permanently. During the first month following stent 
placement, daily factor IX boluses were given in order 
to keep the factor IX plasma level at 30%. Six months 
following angioplasty, the patient remained asymptomatic, 
and his lateral ischemia had resolved. No hemorrhagic event 
was detected. 
DISCUSSION
In this case, the initial intervention indicated was a 
CABG based on the following: (1) Cardiac surgery is 
a relatively safe procedure for hemophilia patients; (2) 
The risks of using anti-platelet drugs are unknown in 
hemophiliacs; and (3) Multi-vessel angioplasty without anti-
platelet treatment should be avoided. After the CABG, the 
patient continued to have angina due to obstruction of the 
saphenous graft. We opted for a single angioplasty based on 
the fact that a second CABG was not indicated for treating 
the remaining single vessel disease. After that, we introduced 
ASA because reports of hemorrhagic complications while 
on ASA are based on a few anecdotal reports,3 and stent 
thrombosis is still a major threat, even in hemophiliacs.4 
This report highlights important issues surrounding the 
treatment of CAD in hemophilia patients: when indicated, 
angiography is a safe procedure and should not be delayed; 
CABG is a feasible option for patients who have multiple 
coronary obstructions, as long as factor IX is properly 
replaced.5 Angioplasty may also be an option for treating this 
hemophilic population, but conclusive evidence is lacking.6 
More importantly, anti-platelet treatment should always be 
considered. 
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